Last Friday, Symphogen presents results from a randomized Phase 2 study with Sym004, a mAb mixture targeting EGFR.
Their report ad results has been selected for oral presentation on 11 September 2017 at the European Society for Medical Oncology (ESMO) 2017 Congress, taking place from 8-12 September 2017, in Madrid, Spain.
“Data from the large Phase 2 study show a remarkable improvement in overall survival in a well-defined patient population suggesting that Sym004 could be a unique precision medicine opportunity for patients with late-stage metastatic colorectal cancer that otherwise have very limited or no treatment options,” says CEO, Martin Olin.
Sym004 is comprised of two antibodies targeting non-overlapping epitopes on EGFR that are designed to not only block ligand induced receptor activation but also to elicit removal of EGFR from the cancer cell surface by inducing receptor internalization and degradation. Positive clinical efficacy findings for Sym004 in patients with metastatic colorectal cancer (mCRC) and with acquired resistance to anti-EGFR antibody was reported in the June 2015 issue of Cancer Discovery (Cancer Discov. 2015 Jun;5(6):598-609).